Keywords: BioAlliance Pharma, Amep, Metastatic melanoma, Herlev Hospital

BioAlliance Pharma updates on Amep biotherapy development

Article | 02 May 2012

Print This

French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has announced the validation by the French drug agency the Afssaps of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in